Sponsored
Article Tools

Pfizer's Agreement To Acquire Baxter’s Portfolio Of Marketed Vaccines Includes Facility in Austria

Published: August 1, 2014; 16:20 · (Vindobona)

Pfizer Inc. announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.

Baxter Biomedizinisches Forschungszentrum Orth to be included in the deal / Picture: © Baxter/APA-Fotoservice/Thomas Preiss

Baxter’s portfolio of marketed vaccines consists of NeisVac-C and FSME-IMMUN/TicoVac.

“Vaccines make a tremendous and valuable impact on public health around the world. They have significantly reduced the threat of widespread and often fatal diseases and every day people of all ages benefit from safe and effective vaccines,” said Susan Silbermann, Pfizer Vaccines…

This article includes a total of 372 words.

or Log In